SLC1A4: A Powerful Prognostic Marker and Promising Therapeutic Target for HCC

Overview of attention for article published in Frontiers in oncology, March 2021

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (70th percentile)
High Attention Score compared to outputs of the same age and source (87th percentile)

Mentioned by

patent: 2 patents

Citations

dimensions_citation: 16 Dimensions

Readers on

mendeley: 12 Mendeley

Summary Patents Dimensions citations

So far, Altmetric has seen 2 patents that reference this research output.

ANTI-SLC1A4 MONOCLONAL ANTIBODIES AND USES THEREOF

Application WO-2024121126-A1

World Intellectual Property Organisation (WIPO)

ANTI-SLC1A4 MONOCLONAL ANTIBODIES AND USES THEREOF

Application EP-4382120-A1

European Patent Office

This page shows the most recent patents that mention this research output.

Click here to find out how to access more activity.